Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

niraparib 4olaparib 2apatinib 2Sevoflurane 2Saline Solution 2Propofol 2Carboplatin 2Bevacizumab 2pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1pazopanib 1palbociclib 1liposomal doxorubicin 1lenvatinib 1gadofosveset trisodium 1fosaprepitant 1ferrous fumarate 1Tranexamic Acid 1Trabectedin 1Sunitinib 1Sodium Chloride 1Pharmacokinetics 1Patient-Specific Modeling 1Pafolacianine 1Paclitaxel 1LY 353381 1Injections 1Indocyanine Green 1Folic Acid 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Ovarian Neoplasms × LY 353381 × Clear all
NCT00190697 2007-05-25

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

Eli Lilly and Company

Phase 4 Completed
70 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡